Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02556736 · ClinicalTrials.gov registry record · Phase 1
AGN-151597 (Formerly RST-001) Phase I/II Trial for Advanced Retinitis Pigmentosa
A Phase 1 study of Advanced Retinitis Pigmentosa, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 4
- Study locations
NCT02556736 is a Phase 1 study of Advanced Retinitis Pigmentosa that has completed, run by AbbVie. The registered enrollment target is 14 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT02556736, a Phase 1 study of Advanced Retinitis Pigmentosa, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 4
- Study locations
Study Summary
All participants in phase 1 and phase 2a had hand motion visual acuity or worse. If efficacy was demonstrated from phase 1, better vision subjects could be enrolled; however, efficacy was not demonstrated.
Conditions Studied
Interventions
- DRUG AGN-151597
Study Locations (4)
California
- University of California San Francisco - Mission Bay /ID# 235717 - San Francisco
Kentucky
- Cincinnati Eye Institute- Edgewood /ID# 236713 - Edgewood
North Carolina
- Duke Eye Center /ID# 235715 - Durham
Texas
- Retina Foundation of the Southwest /ID# 235199 - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2015-12-14 |
| Est. Completion | 2024-10-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02556736
The ClinicalTrials.gov registry entry for NCT02556736 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Retinitis Pigmentosa appearing as the primary indexed condition, and to 1 intervention - of which AGN-151597 is the first listed.
NCT02556736 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Kentucky, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02556736 about?
NCT02556736 is a clinical study titled "AGN-151597 (Formerly RST-001) Phase I/II Trial for Advanced Retinitis Pigmentosa". All participants in phase 1 and phase 2a had hand motion visual acuity or worse. If efficacy was demonstrated from phase 1, better vision subjects could be enrolled; however, efficacy was not demonstrated.
What is the current status of trial NCT02556736?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2015-12-14. Estimated completion is 2024-10-21.
What conditions does trial NCT02556736 study?
This clinical trial studies the following conditions: Advanced Retinitis Pigmentosa.
What interventions are being tested in trial NCT02556736?
The interventions under investigation include: AGN-151597 (DRUG).
Who is sponsoring clinical trial NCT02556736?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02556736 being conducted?
This trial has 4 study locations across California, Kentucky, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.